# Altay Therapeutics — Altay develops disease-modifying therapies targeting transcription…

```yaml
url: "https://forg.to/companies/altay-therapeutics"
website: "http://www.altaytherapeutics.com"
industry: "Healthtech"
company_size: "1-10 employees"
headquarters: "San Francisco, USA"
is_hiring: false
open_roles: 0
verified: false
created: 2026-07-23
```

## About Altay Therapeutics

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer.  Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue.  With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion.  We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue.  With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in pha

## Links

- Website: http://www.altaytherapeutics.com
- Forg: https://forg.to/companies/altay-therapeutics

---
Listed on [Forg](https://forg.to) — the professional network for builders

_HTML version: https://forg.to/companies/altay-therapeutics_